BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB

Rushworth, S, Bowles, KM, Barrera Briceno, LN, Murray, MY, Zaitseva, L and Macewan, DJ (2013) BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. Cellular Signalling, 25 (1). pp. 106-112.

Full text not available from this repository. (Request a copy)
Item Type: Article
Faculty \ School: Faculty of Science > School of Pharmacy
Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:
Depositing User: Users 2731 not found.
Date Deposited: 18 Jan 2013 13:22
Last Modified: 21 Apr 2020 16:11
URI: https://ueaeprints.uea.ac.uk/id/eprint/40855
DOI: 10.1016/j.cellsig.2012.09.008

Actions (login required)

View Item View Item